Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides

Nature Communications

Volumn 5, Issue , 2014, Pages 1-14

  Granados, Diana Paola ^a,b   Sriranganadane, Dev ^a,b   Daouda, Tariq ^a,b   Zieger, Antoine ^a,b   Laumont, Céline M ^a,b   Caron Lizotte, Olivier ^a   Boucher, Geneviève ^a   Hardy, Marie Pierre ^a   Gendron, Patrick ^a   Côté, Caroline ^a   Lemieux, Sébastien ^a,b   Thibault, Pierre ^a,b   Perreault, Claude ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE;

GENOME; HISTOLOGY; IMMUNE RESPONSE; METHODOLOGY; PEPTIDE; POLYMORPHISM;

ADULT; ALLELE; ARTICLE; B LYMPHOBLAST; CASE REPORT; CONTROLLED STUDY; EXOME; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MIDDLE AGED; SIBLING; CHEMISTRY; GENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX;

ALLELES; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDES; POLYMORPHISM, GENETIC;

EID: 84898493547     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4600     Document Type: Article

References (63)

1. de Verteuil, D., Granados, D. P., Thibault, P. & Perreault, C. Origin and plasticity of MHC I-associated self peptides. Autoimmun. Rev. 11, 627-635 (2012)
2. Yewdell, J. W. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 32, 548-558 (2011)
3. Neefjes, J., Jongsma, M. L. M., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823-836 (2011)
4. Davis, M. M. et al. T cells as a self-referential, sensory organ. Annu. Rev. Immunol. 25, 681-695 (2007) (Pubitemid 46697921)
5. Gilchuk, P. et al. Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin. Invest. 123, 1976-1987 (2013)
6. Zarling, A. L. et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl Acad. Sci. USA 103, 14889-14894 (2006) (Pubitemid 44527824)
7. Lemmel, C. et al. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22, 450-454 (2004) (Pubitemid 38451377)
8. Fortier, M. H. et al. The MHC class I peptide repertoire is molded by the transcriptome. J. Exp. Med. 205, 595-610 (2008)
9. Caron, E. et al. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol. Syst. Biol. 7, 533 (2011)
10. Illing, P. T. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486, 554-558 (2012)
11. Croft, N. P. et al. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog. 9, e1003129 (2013)
12. Mester, G., Hoffmann, V. & Stevanovic, S. Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol. Life Sci. 68, 1521-1532 (2011)
13. Bensimon, A., Heck, A. J. & Aebersold, R. Mass spectrometry-based proteomics and network biology. Annu. Rev. Biochem. 81, 379-405 (2012)
14. Milner, E., Barnea, E., Beer, I. & Admon, A. The turnover kinetics of MHC peptides of human cancer cells. Mol. Cell. Proteomics 5, 357-365 (2006) (Pubitemid 43329313)
15. Adamopoulou, E. et al. Exploring the MHC-peptide matrix of central tolerance in the human thymus. Nat. Commun. 4, 2039 (2013)
16. Weinzierl, A. O. et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell. Proteomics 6, 102-113 (2007) (Pubitemid 46152695)
17. Petersdorf, E. W. & Hansen, J. A. New advances in hematopoietic cell transplantation. Curr. Opin. Hematol. 15, 549-554 (2008)
18. The 1000 Genomes Project Consortium et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 55-65 (2012)
19. Granados, D. P. et al. MHC I-associated peptides preferentially derive from transcripts bearing miRNA recognition elements. Blood 119, e181-e191 (2012)
20. Wallny, H. J. & Rammensee, H. G. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343, 275-278 (1990)
21. Simpson, E., Roopenian, D. & Goulmy, E. Much ado about minor histocompatibility antigens. Immunol. Today 19, 108-112 (1998) (Pubitemid 28194655)
22. Roopenian, D., Choi, E. Y. & Brown, A. The immunogenomics of minor histocompatibility antigens. Immunol. Rev. 190, 86-94 (2002) (Pubitemid 36071928)
23. Spierings, E. et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet. 3, e103 (2007)
24. Warren, E. H. et al. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood 120, 2796-2806 (2012)
25. Morse, M. C. et al. The COI mitochondrial gene encodes a minor histocompatibility antigen presented by H2-M3. J. Immunol. 156, 3301-3307 (1996)
26. Wang, W. et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269, 1588-1590 (1995)
27. den Haan, J. M. et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279, 1054-1057 (1998) (Pubitemid 28113311)
28. Simpson, E. & Roopenian, D. Minor histocompatibility antigens. Curr. Opin. Immunol. 9, 655-661 (1997) (Pubitemid 27485293)
29. Zuberi, A. R., Christianson, G. J., Mendoza, L. M., Shastri, N. & Roopenian, D. C. Positional cloning and molecular characterization of an immunodominant cytotoxic determinant of the mouse H3 minor histocompatibility complex. Immunity 9, 687-698 (1998) (Pubitemid 28557597)
30. Klein, C. A. et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J. Exp. Med. 196, 359-368 (2002) (Pubitemid 34875665)
31. Fontaine, P. et al. Adoptive transfer of T lymphocytes targeted to a single immunodominant minor histocompatibility antigen eradicates leukemia cells without causing graft-versus-host disease. Nat. Med. 7, 789-794 (2001) (Pubitemid 32691632)
32. Spierings, E., Wieles, B. & Goulmy, E. Minor histocompatibility antigens-big in tumour therapy. Trends Immunol. 25, 56-60 (2004) (Pubitemid 38167485)
33. Bleakley, M. & Riddell, S. R. Molecules and mechanisms of the graft-versusleukaemia effect. Nat. Rev. Cancer 4, 371-380 (2004)
34. Meunier, M. C. et al. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat. Med. 11, 1222-1229 (2005)
35. Vincent, K., Roy, D. C. & Perreault, C. Next-generation leukemia immunotherapy. Blood 118, 2951-2959 (2011)
36. Warren, E. H. et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplant with T cells specific for minor histocompatibility antigens. Blood 115, 3869-3878 (2010)
37. Hombrink, P. et al. Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach. J. Immunol. 190, 3869-3877 (2013)
38. Yewdell, J. W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3, 952-961 (2003) (Pubitemid 37521537)
39. Perreault, C. The origin and role of MHC class I-associated self-peptides. Prog. Mol. Biol. Transl. Sci. 92, 41-60 (2010)
40. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57-63 (2009)
41. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001) (Pubitemid 32054478)
42. Gebreselassie, D., Spiegel, H. & Vukmanovic, S. Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum. Immunol. 67, 894-906 (2006) (Pubitemid 44828201)
43. Karosiene, E., Lundegaard, C., Lund, O. & Nielsen, M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 64, 177-186 (2012)
44. Akatsuka, Y. et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J. Exp. Med. 197, 1489-1500 (2003) (Pubitemid 36682546)
45. Hassan, C. et al. The human leukocyte antigen-presented ligandome of B lymphocytes. Mol. Cell Proteomics 12, 1829-1843 (2013)
46. Choy, E. et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 4, e1000287 (2008)
47. Popovic, J. et al. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 118, 946-954 (2011)
48. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013)
49. Princiotta, M. F. et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18, 343-354 (2003) (Pubitemid 36351514)
50. de Verteuil, D. et al. Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol. Cell Proteomics 9, 2034-2047 (2010)
51. Spaapen, R. M. et al. Toward targeting B cell cancers with CD4p CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J. Exp. Med. 205, 2863-2872 (2008)
52. Malarkannan, S. et al. Differences that matter: major cytotoxic T cell- stimulating minor histocompatibility antigens. Immunity 13, 333-344 (2000)
53. Bleakley, M. et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8p T cells. Blood 115, 4923-4933 (2010)
54. Kroemer, G. & Zitvogel, L. Can the exome and the immunome converge on the design of efficient cancer vaccines? Oncoimmunology 1, 579-580 (2012)
55. Lennerz, V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013-16018 (2005) (Pubitemid 41552859)
56. Heemskerk, B., Kvistborg, P. & Schumacher, T. N. The cancer antigenome. EMBO J. 32, 194-203 (2013)
57. Zitvogel, L., Galluzzi, L., Smyth, M. J. & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88 (2013)
58. Tosato, G. & Cohen, J. I. Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr. Protoc. Immunol. Chapter 7, Unit 7.22 (2007)
59. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010)
60. Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207-214 (2007) (Pubitemid 46358868)
61. Bollard, C. M. et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110, 2838-2845 (2007) (Pubitemid 350006936)
62. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009)
63. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011)